Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Foresight Biotherapeutics Inc.

Division of Takeda Pharmaceutical Co. Ltd.

Latest From Foresight Biotherapeutics Inc.

The Eyes Have It For Shire With Lifitegrast Filing In Europe

The drug, marketed across the Atlantic as Xiidra, has already made significant inroads in the US dry eye market which has been dominated by Allergan's Restasis

Ophthalmic Approvals

Quick Resubmission Has Shire Seeking Third Quarter Lifitegrast OK

Having produced positive top-line data from a third Phase III trial within two weeks of FDA's complete response letter, Shire made quick work of its reply to the agency on the dry eye disease candidate.

BioPharmaceutical Ireland

Shire Could Get More Out Of OPUS-3 Than Refiling Lifitegrast

Top-line data from the Phase III study of lifitegrast provides first reproducible demonstration of symptom improvement in dry-eye disease ever with a drug therapy. Shire says it remains on track for first quarter refiling of the NDA.

BioPharmaceutical Ireland

Deals Shaping The Medical Industry, September 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2015.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
  • Therapeutic Areas
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Takeda Pharmaceutical Co. Ltd.
  • Senior Management
  • Contact Info
  • Foresight Biotherapeutics Inc.
    Phone: (646) 747-9100
    50 W 57th St.
    New York, NY 10019